医学
支气管扩张
肺活量测定
恶化
生活质量(医疗保健)
物理疗法
肺功能测试
前瞻性队列研究
肺活量
肺功能
内科学
肺
扩散能力
哮喘
护理部
作者
J.M. Bradley,Kathryn M. Ferguson,Andrew Bailey,Katherine O’Neill,Rebecca McLeese,Adam T. Hill,Michael R. Loebinger,Mary Carroll,James D. Chalmers,Timothy Gatheral,Christopher Johnson,Anthony De Soyza,John R. Hurst,D.G. Downey,J. Stuart Elborn
出处
期刊:Annals of the American Thoracic Society
[American Thoracic Society]
日期:2023-05-01
卷期号:20 (5): 648-659
标识
DOI:10.1513/annalsats.202206-493oc
摘要
Rationale: There is a lack of outcome measures with robust clinimetric properties in bronchiectasis. Objectives: To determine the clinimetric properties (reliability over 1 year during clinical stability and responsiveness over the course of antibiotics for pulmonary exacerbation) of objective and patient-reported outcome measures. Methods: This multicenter cohort study included adults with bronchiectasis from seven hospitals in the United Kingdom. Participants attended four visits, 4 months apart over 1 year while clinically stable and at the beginning and end of exacerbation and completed lung function (spirometry and multiple breath washout), provided a blood sample for C-reactive protein (CRP) measurement, and completed health-related quality of life (HRQoL) questionnaires (Quality of Life-Bronchiectasis, St. George’s Respiratory Questionnaire, and EuroQoL 5-Dimensions 5-Levels). Results: Participants (n = 132) had a mean (standard deviation) age of 66 (11) years, and 64% were female. Lung function parameters (forced expiratory volume in one second [FEV1], standard lung clearance index [LCI2.5]) were reliable over time [coefficient of variation (CV): <10%]). Regarding responsiveness, FEV1 demonstrated better properties than LCI2.5; therefore, a clear justification for the use of LCI2.5 in future trials is needed. CRP was less reliable (CV > 20%) over time than FEV1 and LCI2.5, and whereas CRP had a large mean change between the start and end of an exacerbation, this may have been driven by a small number of patients having a large change in CRP. Reliability of HRQoL questionnaires and questionnaire domains ranged from acceptable (CV: 20–30%) to good (CV: 10–20%), and HRQoL were responsive to treatment of exacerbations. Considering the specific questionnaire domain relevant to the intervention and its associated clinimetric properties is important. Additional statistics will support future power and/or sample size analysis. Conclusions: This information on the clinimetric properties of lung function parameters, CRP, and HRQoL parameters should be used to inform the choice of outcome measures used in future bronchiectasis trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI